Ebrahim Umer: The Sickest Liver Patients Deserve One Language – Lessons from the Kyoto Consensus
Ebrahim Umer, Gastroenterology and Hepatology Fellow at St. Paul’s Hospital Millennium Medical College, shared a post on LikedIn:
“The Sickest Liver Patients Deserve One Language – Lessons from the Kyoto Consensus
One of the most important challenges in modern hepatology is that two clinicians may look at the same patient with advanced chronic liver disease and arrive at different diagnoses of Acute-on-Chronic Liver Failure (ACLF) depending on which international criteria they follow.
The concept of ACLF has transformed our understanding of liver decompensation. It is no longer viewed simply as worsening cirrhosis, but rather as a distinct syndrome characterized by acute deterioration, systemic inflammation, organ failure, and high short-term mortality.
Yet, despite its clinical importance, a universal definition remains elusive.
Today, three major societies continue to use different diagnostic frameworks:
- EASL-CLIF focuses heavily on extrahepatic organ failures and grades ACLF according to the number of failed organs.
- APASL emphasizes acute hepatic insult leading to jaundice and coagulopathy, followed by ascites and/or encephalopathy within a defined time frame.
- NACSELD primarily evaluates extrahepatic organ failures in hospitalized patients with cirrhosis.
As a result, the same patient may be classified as ACLF by one society and not by another. This diagnostic heterogeneity affects epidemiology, clinical decision-making, transplant prioritization, research outcomes, and even communication among hepatologists worldwide.
Beyond definitions lies a human reality.
The patient in front of us is not an EASL patient, an APASL patient, or a NACSELD patient. They are a critically ill individual whose prognosis can change dramatically within days. Delayed recognition may mean missed opportunities for intensive management, liver transplantation, or life-saving interventions.
This is why ongoing international efforts toward harmonization are so important.
The emerging Kyoto Consensus represents a significant step toward bridging Eastern and Western perspectives on ACLF. Rather than focusing on differences, it seeks common ground—acknowledging the diverse pathophysiologic pathways of ACLF while moving the field closer to a globally accepted framework for diagnosis, prognostication, and management.
As hepatologists, our ultimate goal is not merely to define ACLF better, but to identify it earlier, treat it more effectively, and improve survival for some of the sickest patients we care for.”
Stay updated with Hemostasis Today.
-
Jun 2, 2026, 15:10Ney Carter Borges: Bempedoic Acid and Venous Thromboembolism Risk in Statin-Intolerant Patients
-
Jun 2, 2026, 15:07Sayan Koley: Coagulation Science – Where Precision Saves Lives
-
Jun 2, 2026, 15:04Ahmed Mohsen: Low CHA₂DS₂-VA Score Does Not Always Mean No Anticoagulation
-
Jun 2, 2026, 15:04The Risk Factors and Optimal Prevention Strategies of VTE in Sickle Cell Disease – RPTH Journal
-
Jun 2, 2026, 14:26PNH and Thrombosis: From Pathogenesis to Complement Inhibition
-
Jun 2, 2026, 14:08Jose Manuel Soria: Can Transcriptomics Improve VTE Risk Prediction?
-
Jun 2, 2026, 14:04Complications of Antiphospholipid Syndrome – APS Awareness Month Day 1 – APS Foundation of America
-
Jun 2, 2026, 14:00Wasimuddin Abdullah: Not Every Hilar ‘Mass’ Is a Mass
-
Jun 2, 2026, 13:53Brian Casey: SNMMI26 Image of the Year Highlights Novel DVT Imaging Technique